TScan Therapeutics, Inc. - Common Stock — Cash Flow (NASDAQ:TCRX) | MetaTrader

Open full chart Full chart

Financials

Overview Statement Statistics

Quarterly Annual

Cash from operating activities -48.68 M-66.5 M-61.36 M-110.82 M-135.32 M -122.01 M Cash from investing activities -9.94 M-4.22 M-60.76 M-52.61 M109.37 M 95.77 M Cash from financing activities 189.67 M29.36 M135.44 M208.76 M-336 K — Free cash flow -48.68 M-66.5 M-61.36 M-110.82 M-139.73 M -124.96 M

News

TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue Estimates

Buy 2 ‘Strong Buy’ Biotech Stocks With 400%+ Upside, According to Wall Street - TipRanks.com

Tscan Therapeutics earnings beat by $0.09, revenue topped estimates

TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Misses Revenue Estimates

TScan completes enrollment in trial cohort, receives FDA clearance

Recursion Pharmaceuticals (RXRX) Reports Q4 Loss, Beats Revenue Estimates

Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Beats Revenue Estimates

Sutro Biopharma (STRO) Surges 11.9%: Is This an Indication of Further Gains?

Roivant Sciences Ltd. (ROIV) Reports Q3 Loss, Misses Revenue Estimates

Tracking Baker Brothers Portfolio – Q3 2025 Update (NASDAQ:INCY)

Tscan Therapeutics stock holds Neutral rating at BTIG after ASH event

TScan to host KOL event discussing updated ALLOHA trial data